Search research articles
Contact Us
Filters
Showing results (281-290 of 738) with videos related to
Page
of 74
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 10, 2006
Human immunodeficiency virus testing in patients with invasive cervical carcinoma: a prospective trial of the gynecologic oncology group
A Calkins, F B Stehman, B Bundy, et al.
The Oncologist
|
July 31, 2023
Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab
Nicoletta Colombo, Domenica Lorusso, Bradley J Monk, et al.
Gynecologic Oncology
|
May 3, 2011
A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study
Robert S Mannel, Mark F Brady, Elise C Kohn, et al.
Future Oncology (London, England)
|
July 6, 2022
Niraparib treatment for patients with <i>BRCA</i>-mutated ovarian cancer: review of clinical data and therapeutic context
Antonio González-Martín, Ursula A Matulonis, Jacob Korach, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 20, 2024
Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe
Kathleen N Moore, Mansoor R Mirza, Charlie Gourley, et al.
Gynecologic Oncology
|
November 12, 2013
Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial
Bradley J Monk, Stanley B Kaye, Andrés Poveda, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe
Kathleen N Moore, Mansoor R Mirza, Charlie Gourley, et al.
Gynecologic Oncology
|
October 12, 2005
Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study
Harry J Long, Bradley J Monk, Helen Q Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2010
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer
Bradley J Monk, Luis Mas Lopez, Juan J Zarba, et al.
Cancer
|
August 20, 2009
Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials
Vivian E von Gruenigen, Helen Q Huang, Karen M Gil, et al.
Page
of 74
Search research articles
Search
Showing results (281-290 of 738) with videos related to
Sort By:
Page
of 74
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 10, 2006
Human immunodeficiency virus testing in patients with invasive cervical carcinoma: a prospective trial of the gynecologic oncology group
A Calkins, F B Stehman, B Bundy, et al.
The Oncologist
|
July 31, 2023
Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab
Nicoletta Colombo, Domenica Lorusso, Bradley J Monk, et al.
Gynecologic Oncology
|
May 3, 2011
A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study
Robert S Mannel, Mark F Brady, Elise C Kohn, et al.
Future Oncology (London, England)
|
July 6, 2022
Niraparib treatment for patients with <i>BRCA</i>-mutated ovarian cancer: review of clinical data and therapeutic context
Antonio González-Martín, Ursula A Matulonis, Jacob Korach, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 20, 2024
Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe
Kathleen N Moore, Mansoor R Mirza, Charlie Gourley, et al.
Gynecologic Oncology
|
November 12, 2013
Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial
Bradley J Monk, Stanley B Kaye, Andrés Poveda, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe
Kathleen N Moore, Mansoor R Mirza, Charlie Gourley, et al.
Gynecologic Oncology
|
October 12, 2005
Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study
Harry J Long, Bradley J Monk, Helen Q Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2010
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer
Bradley J Monk, Luis Mas Lopez, Juan J Zarba, et al.
Cancer
|
August 20, 2009
Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials
Vivian E von Gruenigen, Helen Q Huang, Karen M Gil, et al.
Page
of 74